PR Newswire·Sep 14, 2026, 9:05 AM ET

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

BioMarin Pharmaceutical Inc. appointed Robert Plenge, M.D., Ph.D. to its Board of Directors effective September 10, 2026.
Dr. Plenge currently serves as Executive Vice President, Chief Research Officer, and Head of Research at Bristol Myers Squibb, where he leads scientific work across nine global sites.
His prior experience includes roles as vice president of the immunology and inflammation portfolio at Celgene Corp., vice president and head of translational medicine at Merck & Co., an assistant professor at Harvard Medical School, and an associate member of the Broad Institute.
Dr. Plenge holds an M.D. and Ph.D. from Case Western Reserve University and a bachelor's degree from the University of California, San Diego.
He currently serves on the boards of Alltrna and the PhRMA Foundation.
BioMarin President and CEO Alexander Hardy stated Dr. Plenge's expertise in human genetics will support the company's research capabilities & pipeline expansion for rare diseases.
BioMarin is a San Rafael-based company founded in 1997 with nine commercial therapies & a focus on genetically defined conditions.